Holen Sie sich die Stockscreener-App
2.66
6.67%
-0.19
Schlusskurs vom Vortag:
$2.85
Offen:
$2.83
24-Stunden-Volumen:
965.49K
Relative Volume:
1.12
Marktkapitalisierung:
$96.40M
Einnahmen:
$210.70K
Nettoeinkommen (Verlust:
$-21.37M
KGV:
-2.4182
EPS:
-1.1
Netto-Cashflow:
$-21.10M
1W Leistung:
-6.01%
1M Leistung:
+26.67%
6M Leistung:
+46.96%
1J Leistung:
+64.20%
1-Tages-Spanne:
$2.60
$2.87
1-Wochen-Bereich:
$2.60
$3.05
52-Wochen-Spanne:
$1.41
$3.06
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Vergleichen Sie GANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.66 | 103.29M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
How Gain Therapeutics Inc. stock compares to industry benchmarksWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Gain Therapeutics presents data on GT-02287 - TipRanks
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - The Manila Times
Gain Therapeutics (Nasdaq: GANX) Reports GT-02287 Mitochondrial, Neuronal Data - Stock Titan
Will Gain Therapeutics Inc. stock deliver strong dividend growthInsider Buying & Real-Time Volume Analysis Alerts - newser.com
Gain Therapeutics Inc. stock outlook for YEARJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Is Gain Therapeutics Inc. stock ready for a breakoutWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Can machine learning forecast Gain Therapeutics Inc. recovery2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - sharewise.com
How does Gain Therapeutics Inc (GANX) change from a tortoise to a hare? - Setenews
Is Gain Therapeutics Inc. stock undervalued vs historical averagesQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Equities Analysts Set Expectations for GANX FY2025 Earnings - Defense World
Will Gain Therapeutics Inc. stock go up soon2025 Price Targets & AI Enhanced Trading Signals - newser.com
Can Gain Therapeutics Inc. stock deliver sustainable ROEWeekly Trade Summary & AI Enhanced Trade Execution Alerts - newser.com
Why Gain Therapeutics Inc. stock remains on buy listsJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Is Gain Therapeutics Inc. stock a buy before product launchesMarket Trend Review & Safe Capital Preservation Plans - newser.com
Building trade automation scripts for Gain Therapeutics Inc.Weekly Trading Summary & Verified Momentum Watchlists - newser.com
Gain Therapeutics Reports Continued Progress Amid Financial Challenges - The Globe and Mail
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Day 6 of Gains Streak for Gain Therapeutics Stock with 78% Return (vs. 37% YTD) [11/12/2025] - Trefis
[8-K] Gain Therapeutics, Inc. Reports Material Event | GANX SEC FilingForm 8-K - Stock Titan
[10-Q] Gain Therapeutics, Inc. Quarterly Earnings Report | GANX SEC FilingForm 10-Q - Stock Titan
Gain Therapeutics reports Q3 EPS (15c), consensus (15c) - TipRanks
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics (NASDAQ: GANX) completes Phase 1b enrollment of 21; extension approved - Stock Titan
Sentiment analysis tools applied to Gain Therapeutics Inc.Weekly Market Report & Free High Return Stock Watch Alerts - newser.com
Advanced analytics toolkit walkthrough for Gain Therapeutics Inc.Quarterly Profit Summary & Weekly High Return Forecasts - newser.com
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):